Research Projects Page

Patient reported outcomes can be used to measure therapeutic response, as well as overall health status, functioning, quality of life, and disease management. Patients with inflammatory conditions who fill medication within an integrated HSSP model reported low rates of missed doses and side effects, and most rated high perceived medication effectiveness.

The objective of this study was to measure time to medication access for prescription CBD from patient referral to first shipment when insurance approval process is managed by embedded specialty pharmacy team.

This study evaluates patient characteristics and medication use patterns in patients prescribed cannibidiol for the management of seizure disorders within an integrated care center.

A growing number of institutions are using HCV-positive donor hearts for transplant inHCV-negative recipients. While results of this practice have proven to be successful, management of drug-drug interactions between transplant medications and direct acting antivirals (DAAs) is necessary to ensure safety and efficacy. This study reviews the frequency and type of drug-drug interactions and appropriate management strategies.

This study of patients with RMS and ≥3 fills of DMT from a health-system specialty pharmacy evaluated DMT persistence. The probability of remaining persistent for 3 years was 0.51. Non-persistent patients mostly switched to a new DMT (39%), discontinued the DMT (26%) discontinued, or transferred care to a new specialty pharmacy or provider (27%). Specialty pharmacists played a key role in DMT transitions and initiated 7% of DMT discontinuations and 36% of DMT switches.

This study focuses on HIV PrEP access and affordability.

This study evaluates PCSK9i persistence at 2, 12 and 24 months after initiation of therapy, reasons for non-persistence and percent change in LDL.

This two-part study aimed to identify the rates and reasons of PMN for specialty oral oncolytic agents. In Part I, we used 24 methods to calculate PMN based on combinations of three parameters: lookback window, duplicate window, and fill window.

This report discusses reasons anticancer therapies may need to be initiated on admission, challenges of doing so, perspectives and experiences from 3 unique HSSPs on addressing these challenges, and finally, best practice recommendations in managing high cost oral anticancer therapies for admitted patients.